These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 28416841)
1. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a]. Li XN; Liu AH; Tang X; Ren Y Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841 [TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop. Li X; Wu Y; Liu A; Tang X Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141 [TBL] [Abstract][Full Text] [Related]
3. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. Wu C; Luo J Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938 [TBL] [Abstract][Full Text] [Related]
4. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells. Xu CG; Yang MF; Ren YQ; Wu CH; Wang LQ Eur Rev Med Pharmacol Sci; 2016 Oct; 20(20):4362-4368. PubMed ID: 27831634 [TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Zhu HY; Bai WD; Ye XM; Yang AG; Jia LT Biochem Biophys Res Commun; 2018 Feb; 496(4):1308-1313. PubMed ID: 29408336 [TBL] [Abstract][Full Text] [Related]
6. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206. Ren YQ; Wang HJ; Zhang YQ; Liu YB Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway. Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766 [TBL] [Abstract][Full Text] [Related]
8. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Li Z; Yu D; Li H; Lv Y; Li S Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639 [TBL] [Abstract][Full Text] [Related]
9. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929 [TBL] [Abstract][Full Text] [Related]
10. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Li J; Lu M; Jin J; Lu X; Xu T; Jin S Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449 [TBL] [Abstract][Full Text] [Related]
11. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905 [TBL] [Abstract][Full Text] [Related]
12. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173 [TBL] [Abstract][Full Text] [Related]
13. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803 [TBL] [Abstract][Full Text] [Related]
14. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. Ahmad A; Ginnebaugh KR; Yin S; Bollig-Fischer A; Reddy KB; Sarkar FH BMC Cancer; 2015 Jul; 15():540. PubMed ID: 26206152 [TBL] [Abstract][Full Text] [Related]
15. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Wei Y; Lai X; Yu S; Chen S; Ma Y; Zhang Y; Li H; Zhu X; Yao L; Zhang J Breast Cancer Res Treat; 2014 Sep; 147(2):423-31. PubMed ID: 25007959 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells. Petri BJ; Piell KM; Wilt AE; Howser AD; Winkler L; Whitworth MR; Valdes BL; Lehman NL; Clem BF; Klinge CM Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37650685 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025 [TBL] [Abstract][Full Text] [Related]
18. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Shi YF; Lu H; Wang HB Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279 [TBL] [Abstract][Full Text] [Related]
19. Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b. Fang Q; Chen X; Zhi X Med Sci Monit; 2016 Oct; 22():3506-3513. PubMed ID: 27694794 [TBL] [Abstract][Full Text] [Related]
20. MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3. Li X; Wu Y; Liu A; Tang X Biochem Biophys Res Commun; 2016 Sep; 477(4):768-773. PubMed ID: 27363334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]